PatientsHCP
This site is for US Health Care Professionals only.
Byron Homepage Hero Image

In most patients with HF, help HEART FAILURE MEET HEART SUCCESS1

Start ENTRESTO® to help reduce the risk of CV death and HF hospitalization

Results for HFrEFResults for HFpEF with LVEF ≤60%*

*In PARAGON-HF, defined as LVEF ≥45% with structural heart disease (LAE or LVH); median LVEF was 57%. LVEF is a variable measure and the normal range can vary.1

Starting your patients on ENTRESTO

SEE DOSING

Discover support and resources to help your patients start on ENTRESTO

GET SUPPORT & RESOURCES

Inflation Reduction Act (IRA) – Maximum Fair Price (MFP) for Entresto effective January 1, 2026

For more information about the Entresto MFP effectuation process, online platform for MFP claims adjudication, or any general questions, please visit http://mfp.beaconchannelmanagement.com ↗ or call 1-878-788-8980.

Definitions
ACC, American College of Cardiology; ACEi, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin II receptor blocker; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HFSA, Heart Failure Society of America; LAE, left atrial enlargement; LVEF, left ventricular ejection fraction; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; RASi, renin-angiotensin system inhibitor.

References
1. ENTRESTO [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp.